Korro Bio (KRRO) Director Formela Jean Francois Sells Shares

What Happened

• Formela Jean Francois, a director of Korro Bio, sold a total of 300 shares (249 + 51) in open-market/private sales on August 26, 2026. The reported weighted-average price was $13.96 per share, generating proceeds of approximately $4,188 ($3,476 and $712 respectively). This was a sale (not a purchase) and was executed pursuant to a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-08-26 (reported on Form 4 filed 2026-08-28) — appears timely (filed within the two-business-day window).
• Transaction type/code: Sale (S) — open market or private sale.
• Shares sold: 249 shares and 51 shares (total 300).
• Price: weighted-average $13.96; actual trade prices ranged from $13.955 to $13.98 (per footnote).
• Proceeds: about $4,188 total ($3,476 and $712).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Notable footnotes:
  • Sales executed under a Rule 10b5-1 trading plan established April 8, 2026.
  • Weighted-average price reported; seller can provide breakdown of individual prices on request.
  • Footnotes also reference certain shares held by Atlas Venture funds and disclaimers of Section 16 beneficial ownership (indicating some holdings are held by investment vehicles, not personally).

Context

• Sales under a 10b5-1 plan are pre-scheduled and are generally considered routine execution of previously set instructions rather than ad hoc signals of sentiment. For retail investors, purchases typically carry more informational weight than routine insider sales.